Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Core Viewpoint - A securities class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for allegedly making false and misleading statements regarding its business and the approval process for its Iomab-B BLA [1][2]. Group 1: Allegations and Claims - The lawsuit claims that the defendants failed to disclose that data from the Sierra Trial was unlikely to meet FDA guidelines for the Iomab-B BLA approval [2]. - It is alleged that additional analyses provided to the FDA to support the Sierra Trial's data were also unlikely to satisfy the FDA's requirements [2]. - The complaint suggests that the FDA would likely refuse to review the Iomab-B BLA or that the application would not be approved in its current form [2]. - Defendants' positive statements regarding the company's business and prospects are claimed to be materially misleading [2]. Group 2: Market Reaction - The truth about the inadequacy of the Sierra Trial data began to emerge on August 5, 2024, leading to a significant decline in Actinium's stock price, which harmed investors [3]. Group 3: Investor Information - Investors who acquired shares of Actinium are encouraged to contact the law firm before the lead plaintiff motion deadline on May 26, 2025, to discuss their rights [4].